WO2022007807A1 - Anticorps bispécifique et son utilisation - Google Patents

Anticorps bispécifique et son utilisation Download PDF

Info

Publication number
WO2022007807A1
WO2022007807A1 PCT/CN2021/104810 CN2021104810W WO2022007807A1 WO 2022007807 A1 WO2022007807 A1 WO 2022007807A1 CN 2021104810 W CN2021104810 W CN 2021104810W WO 2022007807 A1 WO2022007807 A1 WO 2022007807A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence shown
sequence
amino acid
antigen
Prior art date
Application number
PCT/CN2021/104810
Other languages
English (en)
Chinese (zh)
Inventor
梁世忠
黄俊杰
梁炳辉
徐振前
俞金泉
李胜峰
Original Assignee
百奥泰生物制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 百奥泰生物制药股份有限公司 filed Critical 百奥泰生物制药股份有限公司
Priority to CN202180047898.6A priority Critical patent/CN115776898A/zh
Publication of WO2022007807A1 publication Critical patent/WO2022007807A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps bispécifique et son utilisation. L'anticorps bispécifique ou le fragment de liaison à l'antigène peut se lier à deux antigènes ou deux épitopes du même antigène. L'anticorps ou le fragment de liaison à l'antigène peut être utilisé pour traiter diverses maladies, telles que des maladies inflammatoires, des maladies auto-immunes, un cancer ou une lésion de la moelle épinière, et peut également être utilisé pour le diagnostic et le pronostic de maladies associées.
PCT/CN2021/104810 2020-07-07 2021-07-06 Anticorps bispécifique et son utilisation WO2022007807A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180047898.6A CN115776898A (zh) 2020-07-07 2021-07-06 双特异性抗体及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010643073 2020-07-07
CN202010643073.8 2020-07-07

Publications (1)

Publication Number Publication Date
WO2022007807A1 true WO2022007807A1 (fr) 2022-01-13

Family

ID=79552784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/104810 WO2022007807A1 (fr) 2020-07-07 2021-07-06 Anticorps bispécifique et son utilisation

Country Status (2)

Country Link
CN (1) CN115776898A (fr)
WO (1) WO2022007807A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198015A1 (fr) * 2022-04-11 2023-10-19 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène se liant spécifiquement à psma et cd28 et son utilisation pharmaceutique
WO2024046389A1 (fr) * 2022-08-31 2024-03-07 百奥泰生物制药股份有限公司 Utilisation combinée d'un anticorps anti-tigit et d'un anticorps anti-ctla-4 dans le traitement d'une tumeur

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781801A (zh) * 2011-08-23 2014-05-07 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
CN106661120A (zh) * 2014-08-04 2017-05-10 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
CN107206072A (zh) * 2014-11-20 2017-09-26 豪夫迈·罗氏有限公司 T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD‑1轴结合拮抗剂的组合疗法
CN107586340A (zh) * 2011-08-23 2018-01-16 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
CN107949574A (zh) * 2015-10-02 2018-04-20 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
CN108026177A (zh) * 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 双特异性抗cd19xcd3 t细胞活化性抗原结合分子
CN109843926A (zh) * 2016-09-30 2019-06-04 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
CN110352200A (zh) * 2018-02-06 2019-10-18 天境生物 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用
WO2020207432A1 (fr) * 2019-04-10 2020-10-15 Bio-Thera Solutions, Ltd. Anticorps se liant à pd-1
WO2021043206A1 (fr) * 2019-09-03 2021-03-11 百奥泰生物制药股份有限公司 Immunosuppresseur anti-tigit et son application

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781801A (zh) * 2011-08-23 2014-05-07 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
CN107586340A (zh) * 2011-08-23 2018-01-16 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
CN106661120A (zh) * 2014-08-04 2017-05-10 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
CN107206072A (zh) * 2014-11-20 2017-09-26 豪夫迈·罗氏有限公司 T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD‑1轴结合拮抗剂的组合疗法
CN107949574A (zh) * 2015-10-02 2018-04-20 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
CN108026177A (zh) * 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 双特异性抗cd19xcd3 t细胞活化性抗原结合分子
CN109843926A (zh) * 2016-09-30 2019-06-04 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
CN110352200A (zh) * 2018-02-06 2019-10-18 天境生物 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用
WO2020207432A1 (fr) * 2019-04-10 2020-10-15 Bio-Thera Solutions, Ltd. Anticorps se liant à pd-1
WO2021043206A1 (fr) * 2019-09-03 2021-03-11 百奥泰生物制药股份有限公司 Immunosuppresseur anti-tigit et son application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JONATHAN S MARVIN, ZHENPING ZHU: "Recombinant approaches to IgG-like bispecific antibodies", ACTA PHARMACOLOGICA SINICA, vol. 26, no. 6, 1 June 2005 (2005-06-01), GB , pages 649 - 658, XP055686455, ISSN: 1671-4083, DOI: 10.1111/j.1745-7254.2005.00119.x *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198015A1 (fr) * 2022-04-11 2023-10-19 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène se liant spécifiquement à psma et cd28 et son utilisation pharmaceutique
WO2024046389A1 (fr) * 2022-08-31 2024-03-07 百奥泰生物制药股份有限公司 Utilisation combinée d'un anticorps anti-tigit et d'un anticorps anti-ctla-4 dans le traitement d'une tumeur

Also Published As

Publication number Publication date
CN115776898A (zh) 2023-03-10

Similar Documents

Publication Publication Date Title
RU2727914C2 (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
WO2020020281A1 (fr) Anticorps anti-tigit et ses utilisations
AU2010220421B2 (en) Antibodies against a proliferating inducing ligand (APRIL)
WO2021238932A1 (fr) Anticorps multi-spécifique et son application
AU2019276486A1 (en) Anti-interleukin-17A antibody, pharmaceutical composition thereof and use thereof
US20240092892A1 (en) Anti-cldn18.2 antibody, and preparation method therefor and use thereof
CN113301919A (zh) 激活免疫细胞的双特异性抗体
US20220348650A1 (en) Anti-tigit immunosuppressant and application thereof
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
WO2022007807A1 (fr) Anticorps bispécifique et son utilisation
JP2022519340A (ja) ヒトｉｌ４ｒａに対する抗体及びその使用
TW201039847A (en) Antibodies against human tweak and uses thereof
WO2024002252A1 (fr) Nanocorps anti-trop2 et son utilisation
JP2020532279A (ja) 抗ｇｉｔｒ抗体、その抗原結合性断片、およびその医薬用途
WO2023143547A1 (fr) Anticorps anti-cd28 et son utilisation
EP4242232A1 (fr) Anticorps bispécifique et son utilisation
WO2022028608A1 (fr) Anticorps anti pd-l1 et son utilisation
WO2022206677A1 (fr) Anticorps anti-vista et son application
AU2020291946A1 (en) Antibodies against PD-1 and methods of use thereof
WO2022247933A1 (fr) ANTICORPS ANTI-SIRPα ET SON UTILISATION
JP6579097B2 (ja) 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体
WO2023193794A1 (fr) Application d'anticorps anti-vista dans un médicament combiné
WO2022262828A1 (fr) Anticorps anti-il-36r et son utilisation
WO2023241493A1 (fr) Anticorps se liant spécifiquement à trop2 ou à son fragment de liaison à l'antigène, son procédé de préparation et son utilisation
WO2024039670A1 (fr) Anticorps anti-cldn4 et leurs méthodes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838663

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21838663

Country of ref document: EP

Kind code of ref document: A1